Xenetic Biosciences Announces Positive Phase 1 Clinical Data for PulmoXen(TM) for Treatment of Cystic Fibrosis
Xenetic Biosciences Appoints Darlene Deptula-Hicks to Board of Directors
Xenetic Biosciences Announces Opening of Corporate Headquarters and R&D Facility in Lexington, MA
Xenetic Biosciences Announces Ticker Symbol Change to XBIO
